WVP
FLXN

Worth Venture Partners’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Worth Venture Partners’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-102,000
Closed -$1.34M – 145
2020
Q2 		$1.34M Buy
+102,000
New +$1.06M 0.66% 23
2019
Q4 		– Sell
-49,350
Closed -$676K – 115
2019
Q3 		$676K Buy
+49,350
New +$586K 0.39% 35

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Worth Venture Partners's FLXN Position: Q3 2020 in Review

Worth Venture Partners sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2020, closing a stake of 102,000 shares — an estimated $1.34M sold.

Worth Venture Partners first reported a position in FLXN in Q3 2019 and held it in 2 quarters. The position peaked at $1.34M in Q2 2020. 135 funds tracked by Wall St. Rank hold FLXN as of Q3 2020.

  • Worth Venture Partners reported no remaining Flexion Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Worth Venture Partners sold 102,000 Flexion Therapeutics, Inc. shares in Q3 2020, an estimated $1.34M.
  • Worth Venture Partners first reported a position in Flexion Therapeutics, Inc. in Q3 2019 and held it in 2 quarters.
  • Worth Venture Partners's Flexion Therapeutics, Inc. position peaked at $1.34M in Q2 2020.
  • 135 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2020.

Based on Worth Venture Partners's 13F filing for Q3 2020, filed 16 Nov 2020.